HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy.

AbstractBACKGROUND:
To evaluate the prognostic impact of surgical intervention for initially-unresectable pancreatic ductal adenocarcinomas with long-term favorable responses to chemotherapy.
METHOD:
Twelve patients with initially-unresectable pancreatic ductal carcinomas who underwent radical surgery after a favorable response to chemotherapy for six months or longer in principle were enrolled in this study. We retrospectively reviewed the charts of these 12 patients and performed a survival analysis.
RESULTS:
Initially, the included patients were unable to undergo resection secondary to locally-advanced disease in eight patients and metastatic disease in four patients. The length of preoperative therapy was five to 44 months (median 12). The operative procedure included resection of the area initially involved by tumor and regional major vessels. The postoperative mortality and morbidity rates were 0% for patients with locally-advanced disease and 50% in those with metastatic disease. R0 resection was achieved in nine patients (75%) and pathological CR was seen in one patient. Estimated overall five-year survival from initial therapy was 50.0%. The survival rate (0% at 5 years) of the four patients with metastatic disease as the cause of initial unresectability was significantly worse than that (100% at 5 years) of the eight patients with locally-advanced disease (P = 0.0014).
CONCLUSION:
Surgical intervention should be considered for patients with initially-unresectable pancreatic cancers who demonstrate long-term favorable responses to chemotherapy. R0 resection may significantly contribute to cure, especially in patients with initially locally-advanced disease. Large cohort prospective studies will be necessary to demonstrate the efficacy of this strategy.
AuthorsKentaro Kato, Satoshi Kondo, Satoshi Hirano, Eiichi Tanaka, Toshiaki Shichinohe, Takahiro Tsuchikawa, Joe Matsumoto
JournalJournal of hepato-biliary-pancreatic sciences (J Hepatobiliary Pancreat Sci) Vol. 18 Issue 5 Pg. 712-6 (Sep 2011) ISSN: 1868-6982 [Electronic] Japan
PMID21455748 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Pancreatic Ductal (drug therapy, mortality, surgery)
  • Chemotherapy, Adjuvant
  • Female
  • Follow-Up Studies
  • Humans
  • Japan (epidemiology)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pancreatectomy (methods)
  • Pancreatic Neoplasms (drug therapy, mortality, surgery)
  • Prognosis
  • Retrospective Studies
  • Survival Rate (trends)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: